Insert Cover Image using Slide Master View Do not distort. Anti-Diabetic Pharmaceuticals Market - India

Transcription

1 Insert Cover Image using Slide Master View Do not distort Anti-Diabetic Pharmaceuticals Market - India March 2012

2 Eecutive Summar Market Drivers and Challenges Drug Regulation and Patents Global Market of Anti-diabetic pharmaceuticals is epected to growth at a CAGR of X% for period Anti-diabetic pharmaceuticals market in India is valued at INR units in Market is epected to grow at a CAGR of m% from to Anti-diabetes therapeutic segment is the second fastest growing segment, after oncolog Drivers: Increase in the number of diabetic patients Introduction of newer and better drugs Increasing aging population Comprehensive health insurances policies covering diabetes Phases of clinical trial Approval and licensing of drugs Patents Challenges: Price regulation in insulin market Use of complementar and alternative medicines Maintainence of health lifestle to avoid diabetes Competition Compan A Compan B Compan C Compan D Compan E Compan F Public Companies Compan G Compan H Compan I Compan J Private Companies 2

3 Introduction Market Overview Drivers & Challenges Government Initiatives Market Value Chain, Regulation and Patents Competition Strategic recommendation 3

4 India s diabetes market is poised to grow over the coming ears Indian Market Overview India is considered to be one of the most lucrative diabetes markets in the world Anti-diabetics represent the second fastest growing therapeutic segment among all the segments,after oncolog Market is epected to grow from INR A bn to INR F bn in, at a CAGR of % Biguanides, Gliclaide, Gliclaidewith metformine, Rosiglitaone and Pioglitaone are the top selling drugs in Indian market Human Miard30/70 is the largest selling insulin in Indian market It showed largest growth among the top 10 brands in Indian Pharmaceutical market Growth in therapeutic segments(2010) oncolog diabetes CVS CNS respirator pain gastro anti-infectives d e f g h c b Market Sie and Growth Market Segmentation a % INR bn X 1 A B e Y 1 C e % Drugs Insulin D e X 2 E e F e Y 2 Source: 4

5 Drivers & Challenges Challenges Drivers Increase in the number of diabetic patients Introduction of newer and better drugs Price regulation in insulin market Competition from complementar and alternative medicines Maintainence of health lifestle to avoid diabetes Increasing aging population Increase in health insurances 5

6 Various initiatives taken b the government is providing a boost to this market Indian Council for Diabetic Care NPCDCS ICDC,registered under Planning Commission, Government of India,is the onl organisation in India providing doorstep diabetes care ICDC implements National Doorstep Diabetes Identification and follow-up programme through Grass Root Level NGOs all over India ICDC affiliates NGOs as Partner Organisation and reach people who are suffering with Diabetes and help them to control diabetes and live without an complications ICDC provides free glucometerand 100 Strips to the NGOs to start identifing the diabetes patients even in villages ICDC is making efforts to provide medical insurance to the diabetes patients through Government of India as in the case of famil planning insurance scheme National Programme for prevention and Control of Diabetes, Cardiovascular diseases and Stroke (NPCDCS) was started in 2008,with the objective of prevention, diagnosis and earl management of diabetes It is alread being implemented in 100 most backward and remote districts spread across 21 states Indian Government plans to etend this programme to all the 650 districts of the countr under the 12 th five ear plan NRHM National Rural Health Mission is providing services for diabetes care in rural India Seeks to provide effective healthcare to rural population throughout the countr with special focus on 18 states Source: 6

7 Major Private Companies - Summar 1, ,000-2,000-3,000-4,000-5,000-6,000-7,000-8,000-9,000-10,000 PAT A B -11,000 Revenue -500, ,000 1,000,000 1,500,000 Sie of the Bubble represents Total Assets in INR XX 2,000,000 2,500,000 C 3,000,000 3,500,000 A B C 7

8 Public: Domestic Compan A Compan (1/3) Compan Information Offices and Centres India Corporate Address Tel No. Fa No. Website Year of Incorporation 19-- Ticker Smbol Stock Echange NNN Products and Services Categor Pharmaceutical Molecule Development X Road Bangalore Products/Services CVD, CNS, respirator, dermatolog, orthopedics, nutritional, urolog, antiinfectives Infectious diseases, metabolic diseases, inflammator/respirator diseases, and oncolog Ke People Name Person M Person N Person O Person Q Cit A Head Office Designation Founder CFO Head President Source: 8

9 Public: Domestic Compan A Compan (2/3) Financial Snapshot Ke Ratios Financial Summar The compan incurred a net loss of INR mn in FY, as compared to net profit of INR mn in FY The compan reported total income of INR bn in FY, registering an increase of per cent over FY The compan earned an operating margin of per cent in FY a decrease of percentage points over FY The compan reported debt to equit ratio of in FY, an increase of per cent over FY Financial Summar Source: Revenue INR mn t s r q 0 Indicators q m Market Capitaliation (INR) Total Enterprise Value (INR) EPS (INR) PE Ratio (Absolute) r n Revenue Profit / Loss s o t p Present Value X mn Y mn Z mn A Profit INR mn p n 0 -m Particulars -o- change Profitabilit Ratios Operating Margin Net Margin Profit Before Ta Margin Return on Equit Return on Capital Emploed Return on Working Capital Return on Assets Return on Fied Assets Cost Ratios Operating costs (% of Sales) Administration costs (% of Sales) Interest costs (% of Sales) Liquidit Ratios Current Ratio Cash Ratio Leverage Ratios Debt to Equit Ratio Debt to Capital Ratio Interest Coverage Ratio Efficienc Ratios Fied Asset Turnover Asset Turnover Current Asset Turnover Working Capital Turnover Capital Emploed Turnover Improved Decline 9

10 Public: Domestic Compan A Compan (3/3) Ke Business Segments Ke Geographic Segments m n o Ke Recent Developments Description News Overview Diabetes Management Ke Initiatives Compan A is an integrated research based compan that produces a wide range of generic medicines Serves customers in over 100 countries with manufacturing facilities in several countries Launched Drug M for the treatment of diabetes Also manufactures Insulin N under its Diabetes management segment Is making consistent effort for continual improvement in rural areas with respect to accessibilit of medicines Source: 10

11 Thank ou for the attention The Anti-Diabetic Pharmaceuticals Market India report is part of Netscribes Healthcare Industr Series. For more detailed information or customied research requirements please contact: Tamojit Ro Netscribes(India) Pvt. Ltd. is dedicated to disseminating information andproviding quick insights on hot industries in India and other emerging markets. Track our new releases and major updates in these industries on About Netscribes Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The compan s epertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients profitabilit and growth objectives. Disclaimer: This report is published for general information onl. Although high standards have been used the preparation, Research on India, Netscribes (India) Pvt. Ltd. or Netscribes is not responsible for an loss or damage arising from use of this document. This document is the sole propert of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction. 11